Compare Barclays PLC (BCS) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Cassava Sciences Inc — how do they compare? Barclays PLC trades at $28.05 (market cap $92.56B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Barclays PLC is far larger — about 1757.7× Cassava Sciences Inc's market cap, and Barclays PLC pays a 1.67% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BCS | FLNA | |
|---|---|---|
Market Cap | $92.56B | $52.66M |
Sector | Financials | Health |
52-Week High | $28.41 | $4.64 |
52-Week Low | $18.48 | $1.09 |
Dividend Yield | 1.67% | — |
Enterprise Value | — | -$33.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
